JP2007520209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520209A5 JP2007520209A5 JP2006541900A JP2006541900A JP2007520209A5 JP 2007520209 A5 JP2007520209 A5 JP 2007520209A5 JP 2006541900 A JP2006541900 A JP 2006541900A JP 2006541900 A JP2006541900 A JP 2006541900A JP 2007520209 A5 JP2007520209 A5 JP 2007520209A5
- Authority
- JP
- Japan
- Prior art keywords
- rejection
- colorant
- bases
- chronic
- cdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001684 chronic effect Effects 0.000 description 5
- 239000003086 colorant Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000009788 parenchymal fibrosis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52672203P | 2003-12-03 | 2003-12-03 | |
| PCT/EP2004/013727 WO2005054503A2 (en) | 2003-12-03 | 2004-12-02 | Biomarkers for graft rejection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009097258A Division JP2009195234A (ja) | 2003-12-03 | 2009-04-13 | 移植片拒絶反応のバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007520209A JP2007520209A (ja) | 2007-07-26 |
| JP2007520209A5 true JP2007520209A5 (enExample) | 2008-01-24 |
| JP4316617B2 JP4316617B2 (ja) | 2009-08-19 |
Family
ID=34652465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541900A Expired - Fee Related JP4316617B2 (ja) | 2003-12-03 | 2004-12-02 | 移植片拒絶反応のバイオマーカー |
| JP2009097258A Pending JP2009195234A (ja) | 2003-12-03 | 2009-04-13 | 移植片拒絶反応のバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009097258A Pending JP2009195234A (ja) | 2003-12-03 | 2009-04-13 | 移植片拒絶反応のバイオマーカー |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20070111210A1 (enExample) |
| EP (1) | EP1694860A2 (enExample) |
| JP (2) | JP4316617B2 (enExample) |
| WO (1) | WO2005054503A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8932808B1 (en) | 2004-01-21 | 2015-01-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for determining a graft tolerant phenotype in a subject |
| WO2006099421A2 (en) | 2005-03-14 | 2006-09-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for evaluating graft survival in a solid organ transplant recipient |
| USRE46843E1 (en) | 2005-03-14 | 2018-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for evaluating graft survival in a solid organ transplant recipient |
| GB0605217D0 (en) * | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
| GB0606776D0 (en) * | 2006-04-03 | 2006-05-10 | Novartis Pharma Ag | Predictive biomarkers for chronic allograft nephropathy |
| GB0607943D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Biomarkers for chronic transplant dysfunction |
| CA2650507A1 (en) * | 2006-04-27 | 2007-11-08 | Universite De Montreal | Assessment and reduction of risk of graft-versus-host disease |
| WO2008009132A1 (en) * | 2006-07-21 | 2008-01-24 | The Governors Of The University Of Alberta | Tissue rejection |
| EP2066809A2 (en) * | 2006-08-28 | 2009-06-10 | Source Precision Medicine | Gene expression profiling for identification, monitoring and treatment of transplant rejection |
| JP2008151517A (ja) * | 2006-12-14 | 2008-07-03 | Niigata Univ | 腎障害の判定方法 |
| EP2031073A1 (en) * | 2007-08-31 | 2009-03-04 | TC LAND Expression | Diagnostic of immune graft tolerance using TMTC3 gene expression levels |
| EP2279270B1 (en) * | 2008-04-15 | 2014-06-18 | Oberbauer, Rainer | Markers of acute kidney failure |
| US20110201519A1 (en) | 2008-08-18 | 2011-08-18 | Sarwal Minnie M | Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject |
| CN102439172B (zh) | 2009-01-15 | 2017-03-01 | 小利兰·斯坦福大学托管委员会 | 用于诊断和预测移植物排斥的生物标志物板 |
| WO2010093869A1 (en) * | 2009-02-12 | 2010-08-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for monitoring allograft rejection |
| EP3185013B1 (en) | 2009-12-02 | 2019-10-09 | The Board of Trustees of the Leland Stanford Junior University | Biomarkers for determining an allograft tolerant phenotype |
| US9535075B2 (en) | 2010-03-25 | 2017-01-03 | The Board Of Trustees Of The Leland Stanford Junior University | Protein and gene biomarkers for rejection of organ transplants |
| US20130252839A1 (en) * | 2010-10-17 | 2013-09-26 | Sahar Elhanan | Markers of primary graft dysfunction |
| WO2012139051A2 (en) | 2011-04-06 | 2012-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Autoantibody biomarkers for iga nephropathy |
| US20140080128A1 (en) * | 2011-05-18 | 2014-03-20 | Institut National de Ia Sante et de la Recherche Medicale (INSERM) | Method for determining whether a subject is at risk of having or developing a chronic kidney disease |
| US20150293131A1 (en) * | 2012-04-02 | 2015-10-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of sepsis |
| EP2671574A1 (en) | 2012-06-04 | 2013-12-11 | VitaK B.V. | Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation |
| PL2875049T3 (pl) * | 2012-07-18 | 2019-07-31 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd) |
| WO2016097259A1 (en) * | 2014-12-19 | 2016-06-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting graft alterations |
| JP6842195B2 (ja) | 2016-12-19 | 2021-03-17 | 国立大学法人大阪大学 | インビトロでのＩｇＭ型メモリーＢ細胞分化培養系を用いた臓器移植後抗体関連型拒絶反応の早期診断法 |
| CN110960672B (zh) * | 2019-12-18 | 2020-10-16 | 西南民族大学 | 一种提高牦牛免疫能力的aif-1蛋白注射液 |
| WO2025199256A1 (en) * | 2024-03-20 | 2025-09-25 | Alkahest, Inc. | Longitudinal sample sets and methods of making and using the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527884A (en) * | 1993-12-21 | 1996-06-18 | President And Fellows Of Harvard College | Mediators of chronic allograft rejection and DNA molecules encoding them |
| US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| US20030104371A1 (en) * | 1997-09-24 | 2003-06-05 | Strom Terry B. | Methods of evaluating transplant rejection |
| US6187534B1 (en) * | 1997-09-24 | 2001-02-13 | Cornell Research Foundation, Inc. | Methods of evaluating transplant rejection |
| WO2002092124A1 (en) * | 2001-05-11 | 2002-11-21 | Wyeth | Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof |
| US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| GB0200929D0 (en) * | 2002-01-16 | 2002-03-06 | Univ Glasgow | Tissue rejection |
| ATE546547T1 (de) * | 2002-08-22 | 2012-03-15 | Novartis Pharma Gmbh | Diagnose der chronischen abstossung |
-
2004
- 2004-12-02 JP JP2006541900A patent/JP4316617B2/ja not_active Expired - Fee Related
- 2004-12-02 US US10/581,068 patent/US20070111210A1/en not_active Abandoned
- 2004-12-02 WO PCT/EP2004/013727 patent/WO2005054503A2/en not_active Ceased
- 2004-12-02 EP EP04801199A patent/EP1694860A2/en not_active Withdrawn
-
2009
- 2009-04-13 JP JP2009097258A patent/JP2009195234A/ja active Pending
- 2009-07-13 US US12/501,706 patent/US20090269334A1/en not_active Abandoned
-
2011
- 2011-10-25 US US13/280,839 patent/US20120039868A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kurian et al. | Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling | |
| McBride et al. | Linkage analysis of left ventricular outflow tract malformations (aortic valve stenosis, coarctation of the aorta, and hypoplastic left heart syndrome) | |
| Al-Kafaji et al. | Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker | |
| DK2598659T3 (en) | PROCEDURE FOR USING GENEPRESSION FOR DETERMINING PROSTATE CANCER FORECAST | |
| Neumann et al. | MicroRNA 628-5p as a novel biomarker for cardiac allograft vasculopathy | |
| EP2904118B1 (en) | Urine exosome mrnas and methods of using same to detect diabetic nephropathy | |
| JP2013519095A5 (enExample) | ||
| KR20170107934A (ko) | 동맥경화증 및 이와 관련된 허혈성 심장질환의 진단용 바이오마커 | |
| JP2012517592A5 (enExample) | ||
| Nakashima et al. | Lifelong clinical impact of the presence of sarcomere gene mutation in Japanese patients with hypertrophic cardiomyopathy | |
| Liu et al. | Association of miR-197-5p, a circulating biomarker for heart failure, with myocardial fibrosis and adverse cardiovascular events among patients with stage C or D heart failure | |
| Tran et al. | Association between AGT M235T and left ventricular mass in Vietnamese patients diagnosed with essential hypertension | |
| Kiewisz et al. | WNT4 expression in primary and secondary kidney diseases: dependence on staging | |
| US20060003338A1 (en) | System and methods for the management and treatment of vascular graft disease | |
| US20190390275A1 (en) | Chronic kidney disease diagnostic | |
| ES2380929T3 (es) | Diagnóstico de rechazo crónico | |
| WO2012150863A1 (en) | Means and methods to determine a risk of multiple organ failure | |
| Song et al. | Integrated strategies of diverse feature selection methods identify aging-based reliable gene signatures for ischemic cardiomyopathy | |
| Abd El-Fattah et al. | Association of genetic variants of hemostatic genes with myocardial infarction in Egyptian patients | |
| CN105132565A (zh) | 用于心脏病诊断和分型的超敏分子标志物及其应用 | |
| Hohenadel et al. | Gene expression in diabetic nephropathy | |
| Badr et al. | Association of genetic variants of pentraxin 3 rs3816527 with hypertension in Chronic kidney disease patients | |
| CN108004316A (zh) | 用于预测急性心肌梗死风险的试剂盒 | |
| Halpern et al. | Lgr5+ telocytes are a signaling hub at the intestinal villus tip | |
| Bayanova et al. | Genetic biomarkers of acute graft rejection after heart transplantation |